Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Common Equity (2016 - 2025)

Cytosorbents' Common Equity history spans 15 years, with the latest figure at $5.9 million for Q4 2025.

  • Quarterly results put Common Equity at $5.9 million for Q4 2025, down 46.85% from a year ago — trailing twelve months through Dec 2025 was $5.9 million (down 46.85% YoY), and the annual figure for FY2025 was $5.9 million, down 46.85%.
  • Common Equity for Q4 2025 was $5.9 million at Cytosorbents, down from $9.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $77.3 million in Q1 2021 to a low of $5.9 million in Q4 2025.
  • The 5-year median for Common Equity is $24.0 million (2023), against an average of $33.1 million.
  • The sharpest move saw Common Equity skyrocketed 262.49% in 2021, then plummeted 52.7% in 2024.
  • Year by year, Common Equity stood at $62.6 million in 2021, then crashed by 43.47% to $35.4 million in 2022, then tumbled by 33.63% to $23.5 million in 2023, then tumbled by 52.7% to $11.1 million in 2024, then plummeted by 46.85% to $5.9 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $5.9 million, $9.0 million, and $11.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.